Florida  Biologix (Alachua, FL), a biopharmaceutical development and contract  manufacturing organization, has entered into a current good manufacturing  practices (cGMP) manufacturing agreement with the National Taiwan University  Hospital (Taipei, Taiwan). Under the agreement, Florida Biologix will produce a  Phase 1 clinical batch of a novel therapy for the rare genetic disease,  aromatic amino acid decarboxylase (AADC) deficiency.

News

Florida Biologix (Alachua, FL), a biopharmaceutical development and contract manufacturing organization, has entered into a current good manufacturing practices (cGMP) manufacturing agreement with the National Taiwan University Hospital (Taipei, Taiwan).